FRANKFURT (dpa-AFX) - The investment bank Oddo BHF has downgraded Schott Pharma from "Outperform" to "Neutral" after the final figures for the financial year, but raised its target price from 33 to 34 euros. After a good run since the IPO, the shares have reached his price target, wrote analyst Oliver Metzger in a study published on Monday. He now no longer sees sufficient price potential to justify a continued positive vote. A comparison with the competition also makes the valuation of the share appear appropriate./tih/ajx

Publication of the original study: 26.01.2024 / 18:15 / CET

First dissemination of the original study: 29.01.2024 / 08:26 / CET